Aeromonas hydrophila bacteriophage Aer-HYP-3 and use thereof for inhibiting growth of Aeromonas hydrophila bacteria
Inventors
Yoon, Seong Jun • JUN, Soo Youn • KWON, An Sung • Jung, Ji In • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11844818-B2
Publication Date
2023-12-19
Expiration Date
Abstract
The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.
Core Innovation
The invention relates to the bacteriophage Aer-HYP-3 of the family Myoviridae, deposited as KCTC 13479BP and described with a genome consisting of a sequence as set forth in SEQ ID NO: 1. The bacteriophage Aer-HYP-3 is characterized by genome sequencing, novelty relative to BLAST homology, and distinct ORF counts.
The bacteriophage Aer-HYP-3 has an ability to kill Aeromonas hydrophila. Selective killing of Aeromonas hydrophila strains is described, together with no activity against multiple non-target bacteria in the partial content.
The document further describes preventing and treating a disease caused by Aeromonas hydrophila by administering a composition having Aer-HYP-3 as an active ingredient to an animal other than a human. Use cases described include in vitro growth inhibition, prevention and treatment in rainbow trout, and reduced mortality in farming through formulations described as a feed additive and a medicine bath agent/immersion agent containing Aer-HYP-3.
Claims Coverage
The provided independent claims are clm-00001 and clm-00003. Both claims focus on preventing and treating a disease caused by Aeromonas hydrophila using the specific Myoviridae bacteriophage Aer-HYP-3 (KCTC 13479BP) with a genome sequence as set forth in SEQ ID NO: 1, with different administration formats.
Immersing an animal with Aer-HYP-3 in a composition
A method of preventing and treating a disease caused by Aeromonas hydrophila, comprising immersing an animal other than a human in a composition comprising, as the active ingredient, a Myoviridae bacteriophage Aer-HYP-3 (KCTC 13479BP) having an ability to kill Aeromonas hydrophila and a genome consisting of a sequence as set forth in SEQ ID NO: 1.
Administering Aer-HYP-3 composition to an animal
A method of preventing and treating a disease caused by Aeromonas hydrophila, comprising administering to an animal other than a human the composition comprising, as the active ingredient, a Myoviridae bacteriophage Aer-HYP-3 (KCTC 13479BP) having an ability to kill Aeromonas hydrophila and a genome consisting of a sequence as set forth in SEQ ID NO: 1.
Across the independent claims, the inventive subject matter is the use of the specific Myoviridae bacteriophage Aer-HYP-3 (KCTC 13479BP) with a genome sequence as set forth in SEQ ID NO: 1, and the method of preventing and treating Aeromonas hydrophila disease in an animal other than a human via immersion or administration, respectively.
Stated Advantages
Selective killing of Aeromonas hydrophila strains (13/15 tested) is described.
No activity against multiple non-target bacteria is described in the partial content.
In vitro growth inhibition is described.
Prevention and treatment outcomes in rainbow trout are described, including reduced ulcer scores and furunculosis outcomes.
Reduced mortality in farming using formulations containing Aer-HYP-3 is described.
Documented Applications
In vitro growth inhibition against Aeromonas hydrophila is described.
Prevention and treatment in rainbow trout for disease outcomes including reduced ulcer scores and furunculosis outcomes are described.
Disease control in farming is described using a feed additive and a medicine bath agent/immersion agent formulations containing Aer-HYP-3, with reduced mortality outcomes.
Interested in licensing this patent?